Annuncio • Jun 25
Moamena Abdul Wahab Kamel and Hend El Sherbini of Integrated Diagnostics Holdings plc acquired an additional 21.67% stake in Integrated Diagnostics Holdings plc (LSE:IDHC) from Actis LLP for $63 million. Moamena Abdul Wahab Kamel and Hend El Sherbini of Integrated Diagnostics Holdings plc acquired an additional 21.67% stake in Integrated Diagnostics Holdings plc (LSE:IDHC) from Actis LLP for $63 million on June 22, 2026. A cash consideration valued at $0.5 per share will be paid by the buyer. As part of consideration, an undisclosed value is paid towards common equity of Integrated Diagnostics Holdings plc.The Elliott Transaction and the Offer has been financed by (i) a loan made byRNAFIII Cooperatief U.A. and RMBV2 (together, "RMBV") to Bidcoin the amount of up to $60 million (the "RMBV Loan"); and (ii) equity subscriptions to be made by Hend El Sherbini and Moamena Abdul Wahab Kamel in an amount of not less than $43 million and not more than $150 million. The Elliott Transaction was financed by a $20 million drawdown from the RMBV Loan; and equity subscriptions made by Hend El Sherbini and Moamena Abdul Wahab Kamel in an amount of $43 million. Bidco does not intend to effect any material change with regard to: (i) the headcount of IDH's employees and managers and (ii) the conditions of employment or balance of skills and functions of the management or employees of IDH. In a related transaction Moamena Abdul Wahab Kamel and Hend El Sherbini will acquire all the remaining stake of Integrated Diagnostics Holdings plc.
Stuart Andrews and Harry Rees of Canaccord Genuity Limited acted as financial advisor for Moamena Abdul Wahab Kamel and Hend El Sherbini. James Thompson, Hani Nassef, Ben Wilkinson, Tom Quincey and Lamyaa Gadelhak of Baker & McKenzie LLP acted as legal advisor for Moamena Abdul Wahab Kamel and Hend El Sherbini.
Moamena Abdul Wahab Kamel and Hend El Sherbini of Integrated Diagnostics Holdings plc completed the acquisition of an additional 21.67% stake in Integrated Diagnostics Holdings plc (LSE:IDHC) from Actis LLP on June 22, 2026. Annuncio • May 22
Integrated Diagnostics Holdings plc Approves Final Dividend for the Year Ended 31 December 2025 Integrated Diagnostics Holdings plc at its Annual General Meeting held on May 19, 2026 approved to declare a final dividend of USD 0.0085 per Share in respect of the year ended 31 December 2025. Annuncio • May 21
Integrated Diagnostics Holdings plc to Report Q1, 2026 Results on May 20, 2026 Integrated Diagnostics Holdings plc announced that they will report Q1, 2026 results on May 20, 2026 Annuncio • May 20
Integrated Diagnostics Holdings plc to Report Q1, 2026 Results on May 25, 2026 Integrated Diagnostics Holdings plc announced that they will report Q1, 2026 results on May 25, 2026 Annuncio • Apr 21
Integrated Diagnostics Holdings plc, Annual General Meeting, May 19, 2026 Integrated Diagnostics Holdings plc, Annual General Meeting, May 19, 2026. Location: strand hanson ltd, 26 mount row, mayfair, w1k 3sq, london United Kingdom Annuncio • Apr 19
Integrated Diagnostics Holdings plc Recommends Cash Dividend for the Year Ended December 31, 2025 , Payable on June 22, 2026 Integrated Diagnostics Holdings plc recommended that a cash dividend of USD 4.9 million (USD 0.0085 per share), for the year ended December 31, 2025, should be paid to shareholders who appear on the register as of 29 May 2026, with an ex-dividend date of 28 May 2026. The payment date for the dividend will be 22 June 2026. Proposed dividends for ordinary shares are subject to the approval of the Annual General Meeting (AGM) and are not recognised as a liability as of 31 December 2025. Annuncio • Nov 07
Integrated Diagnostics Holdings plc to Report Nine Months, 2025 Results on Nov 13, 2025 Integrated Diagnostics Holdings plc announced that they will report nine months, 2025 results on Nov 13, 2025 Annuncio • Sep 04
Integrated Diagnostics Holdings plc Provides Earnings Guidance for the Full Year 2025 Integrated Diagnostics Holdings plc provided earnings guidance for the full year 2025. for the year, the company expects revenue growth coming in above 30%. Annuncio • Aug 29
Integrated Diagnostics Holdings plc to Report Q2, 2025 Results on Sep 02, 2025 Integrated Diagnostics Holdings plc announced that they will report Q2, 2025 results at 6:00 AM, Coordinated Universal Time on Sep 02, 2025 Annuncio • May 22
Integrated Diagnostics Holdings plc to Report Q1, 2025 Results on May 28, 2025 Integrated Diagnostics Holdings plc announced that they will report Q1, 2025 results at 6:00 AM, Coordinated Universal Time on May 28, 2025 Annuncio • Apr 25
Integrated Diagnostics Holdings plc, Annual General Meeting, May 27, 2025 Integrated Diagnostics Holdings plc, Annual General Meeting, May 27, 2025. Location: 2 more london riverside, se1 2jt, london United Kingdom Annuncio • Apr 10
Integrated Diagnostics Holdings plc to Report Fiscal Year 2024 Results on Apr 17, 2025 Integrated Diagnostics Holdings plc announced that they will report fiscal year 2024 results at 6:00 AM, Coordinated Universal Time on Apr 17, 2025 Annuncio • Nov 12
Integrated Diagnostics Holdings plc to Report Nine Months, 2024 Results on Nov 14, 2024 Integrated Diagnostics Holdings plc announced that they will report nine months, 2024 results on Nov 14, 2024 Annuncio • Sep 05
Integrated Diagnostics Announces Completion of the Egyptian Exchange Delisting Integrated Diagnostics Holdings plc refers to: the shareholder resolutions passed at the Company's Extraordinary General Meetings held on 12 June 2024 and 18 July 2024 approving, amongst other things, the voluntary delisting (the ‘EGX Delisting’) of the Company's ordinary shares (the ‘Shares’) from the Egyptian Exchange (the ‘EGX’) and the Company's repurchase of Shares from the beneficial owners of the Shares that were traded on the EGX and held by Misr for Central Clearing, Depository and Registry (‘MCDR’) (‘EGX Shares’)if so required by such beneficial owners during the relevant period; the Company's announcement on 13 August 2024 in relation to the timeline for the share buyback under the EGX's special operations market (OPR); and the Company's announcement on 27 August 2024 in relation to the share buyback under the EGX's special operations market (OPR). Further to the Company's repurchase of 18,673,728 EGX Shares on 26 August 2024 pursuant to the share buyback under the EGX's special operations market (OPR), the EGX's Listing Committee has, on 4 September 2024, published its formal decision to delist the Shares from the EGX. As a result, the Company's listing information has been removed from the EGX's database, effective as at the commencement of the trading session on 5 September 2024. Accordingly, the EGX Delisting has become effective and completed on 4 September 2024, and the last trading date of the Shares on the EGX was 4 September 2024. The Shares remain admitted to the equity shares (transition) category (previously, the standard listing segment) of the Official List of the UK Financial Conduct Authority and admitted to trading on the main market for listed securities of the London Stock Exchange (the ‘LSE’), which is now the sole listing venue of the Company. Following the completion of the EGX Delisting, all remaining EGX Shares that were not validly tendered into the EGX's special operations market (OPR) and repurchased by the Company pursuant to the share buyback are no longer capable of being traded on the EGX (such EGX Shares, the ‘Remaining Shares’). Annuncio • May 29
Integrated Diagnostics Holdings plc to Report Q1, 2024 Results on May 30, 2024 Integrated Diagnostics Holdings plc announced that they will report Q1, 2024 results at 6:00 AM, Coordinated Universal Time on May 30, 2024 Annuncio • May 03
Integrated Diagnostics Holdings plc, Annual General Meeting, May 29, 2024 Integrated Diagnostics Holdings plc, Annual General Meeting, May 29, 2024, at 14:00 Coordinated Universal Time. Location: 2 More London Riverside, London, SE1 2JT London United Kingdom Agenda: To receive and consider the Company’s Audited Financial Statements, together with the Reports of the Directors and the Auditor for the year ended 31 December 2023; to consider Lord Anthony Tudor St John, who retires as a director and, being eligible, offers himself for re-election at the AGM, be re-elected; to consider Dr. Hend El-Sherbini, who retires as a director and, being eligible, offers herself for re-election at the AGM, be re-elected; and to consider other matters of business. Annuncio • Sep 01
Integrated Diagnostics Holdings Reaffirms Revenue Guidance for the Fiscal Year 2023 Integrated Diagnostics Holdings reaffirmed revenue guidance for the fiscal year 2023. Considering their strong first half results, the solid strategies in place, and the positive momentum enjoyed by the Egyptian and Jordian subsidiaries, the company reaffirms their guidance of full-year conventional revenue (excluding Covid-19-related contributions) year-on-year growth of around 30% for fiscal year 2023. Annuncio • Aug 31
Integrated Diagnostics Holdings plc to Report First Half, 2023 Results on Aug 31, 2023 Integrated Diagnostics Holdings plc announced that they will report first half, 2023 results on Aug 31, 2023 Annuncio • May 05
Integrated Diagnostics Holdings plc, Annual General Meeting, May 30, 2023 Integrated Diagnostics Holdings plc, Annual General Meeting, May 30, 2023, at 14:00 Coordinated Universal Time. Location: 2 More London Riverside, London, SE1 2JT London United Kingdom Agenda: To consider the Company's Audited Financial Statements, together with the Reports of the Directors and the Auditor for the year ended 31 December 2022; to consider Lord Anthony Tudor St John, who retires as a director and, being eligible, offers himself for re-election at the AGM, be re-elected; to consider Dan Johan Wilmar Olsson, who retires as a director and, being eligible, offers himself for re-election at the AGM, be re-elected; to consider Hussein Hassan Choucri, who retires as a director and, being eligible, offers himself for re-election at the AGM, be re-elected; to consider Yvonne Stillhart, who retires as a director and, being eligible, offers herself for re-election; to consider re-appoint PricewaterhouseCoopers LLP as Auditor; and to consider other matters. Annuncio • Feb 01
Integrated Diagnostics Holdings to No Longer Pursue Acquisition of IDC Stake Integrated Diagnostics Holdings plc (LSE:IDHC) announced that it will no longer pursue negotiations for the acquisition of a 50% stake in Islamabad Diagnostic Center ("IDC"). The Group has notified Evercare IGA Holdings Limited (a company managed by TPG Inc., the "Seller") of its decision which comes at the end of an eighteen-month process that saw the parties work closely together to bring the transaction to completion. While the original share purchase agreement (the "SPA"), which had been signed on 20 December 2021, expired on 29 August 2022, IDH and the Seller continued negotiations aimed at concluding a transaction on modified terms. Despite the efforts of the parties, extensive delays in the regulatory review process, the challenging global economic environment and the condition precedent related to repatriating funds, have resulted in the discontinuation of negotiations towards completing the transaction. As always, IDH continues to assess potential value-accretive acquisition opportunities in new markets across Africa, the Middle East, and Asia where it feels its business model is best-suited to capitalise on healthcare and consumer trends similar to those prevailing in our current markets of operation. 
